Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland
Abstract Key points The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also. Backg...
Gespeichert in:
| Veröffentlicht in: | Journal of the Pediatric Infectious Diseases Society 2017-11, Vol.6 (4), p.317-323 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 323 |
|---|---|
| container_issue | 4 |
| container_start_page | 317 |
| container_title | Journal of the Pediatric Infectious Diseases Society |
| container_volume | 6 |
| creator | Hemming-Harlo, Maria Vesikari, Timo Uhari, Matti Renko, Marjo Salminen, Marjo Torcel-Pagnon, Laurence Hartwig, Susanne Simondon, Francois Bricout, Hélène |
| description | Abstract
Key points
The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also.
Background
Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up.
Methods
Between 2009 and 2013, we conducted a prospective surveillance study of children aged |
| doi_str_mv | 10.1093/jpids/piw061 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7107484</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jpids/piw061</oup_id><sourcerecordid>1835504238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-423ef233947b2012e812d0f59669c933f87a67fb06c18d8750d5d3db0acf23103</originalsourceid><addsrcrecordid>eNp9kUFvFCEYhidGY5vam2fDTQ-OhYEZmIvJprZdkyYmWg-eCMPA9mtmYcrHrNGf4K8Wu22jF7lAwsPzveStqpeMvmO05yc3M4x4MsN32rEn1WFDhaplQ-XThzPr-UF1jHhDy-pa1irxvDpopOyoovSw-vVlwWwguJGsYXNNzrx3NsPOBYdIoiefYzZX7pbEQNYRZ8hmgp8mQwxIVjknGJZshsmRHO_YHaQF6xVitGBy0V4YzCm6kF2CDEg-LAnChgjyzZmEBAI5hzCZML6onnkzoTu-34-qr-dnV6fr-vLTxcfT1WVthRC5Fg13vuG8F3JoKGucYs1Ifdt3XW97zr2SppN-oJ1lalSypWM78nGgxpZnjPKj6v3eOy_D1o22REtm0nOCrUk_dDSg_70JcK03caclo1IoUQRv7gUp3i4Os94CWjeVT7i4oGaKty0tOVVB3-5RmyJicv5xDKP6T4P6rkG9b7Dgr_6O9gg_9FWA13sgLvP_Vb8Bl6upew</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835504238</pqid></control><display><type>article</type><title>Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Hemming-Harlo, Maria ; Vesikari, Timo ; Uhari, Matti ; Renko, Marjo ; Salminen, Marjo ; Torcel-Pagnon, Laurence ; Hartwig, Susanne ; Simondon, Francois ; Bricout, Hélène</creator><creatorcontrib>Hemming-Harlo, Maria ; Vesikari, Timo ; Uhari, Matti ; Renko, Marjo ; Salminen, Marjo ; Torcel-Pagnon, Laurence ; Hartwig, Susanne ; Simondon, Francois ; Bricout, Hélène</creatorcontrib><description>Abstract
Key points
The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also.
Background
Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up.
Methods
Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as “cases” and rotavirus-negative children as “controls.” Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001–2006) and post-NIP seasons (2009–2013).
Results
The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%–98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons.
Conclusions
Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.</description><identifier>ISSN: 2048-7193</identifier><identifier>EISSN: 2048-7207</identifier><identifier>DOI: 10.1093/jpids/piw061</identifier><identifier>PMID: 27760800</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Child ; Child, Preschool ; Editor's Choice ; Enzyme-Linked Immunosorbent Assay ; Finland - epidemiology ; Gastroenteritis - epidemiology ; Gastroenteritis - prevention & control ; Gastroenteritis - virology ; Hospitalization - statistics & numerical data ; Humans ; Infant ; Infant, Newborn ; Original ; Population Surveillance ; Reverse Transcriptase Polymerase Chain Reaction ; Rotavirus - genetics ; Rotavirus Infections - diagnosis ; Rotavirus Infections - epidemiology ; Rotavirus Infections - prevention & control ; Rotavirus Infections - virology ; Rotavirus Vaccines - therapeutic use ; Seasons ; Treatment Outcome ; Vaccines, Attenuated - therapeutic use</subject><ispartof>Journal of the Pediatric Infectious Diseases Society, 2017-11, Vol.6 (4), p.317-323</ispartof><rights>The Author 2016. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2016</rights><rights>The Author 2016. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-423ef233947b2012e812d0f59669c933f87a67fb06c18d8750d5d3db0acf23103</citedby><cites>FETCH-LOGICAL-c444t-423ef233947b2012e812d0f59669c933f87a67fb06c18d8750d5d3db0acf23103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27760800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hemming-Harlo, Maria</creatorcontrib><creatorcontrib>Vesikari, Timo</creatorcontrib><creatorcontrib>Uhari, Matti</creatorcontrib><creatorcontrib>Renko, Marjo</creatorcontrib><creatorcontrib>Salminen, Marjo</creatorcontrib><creatorcontrib>Torcel-Pagnon, Laurence</creatorcontrib><creatorcontrib>Hartwig, Susanne</creatorcontrib><creatorcontrib>Simondon, Francois</creatorcontrib><creatorcontrib>Bricout, Hélène</creatorcontrib><title>Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland</title><title>Journal of the Pediatric Infectious Diseases Society</title><addtitle>J Pediatric Infect Dis Soc</addtitle><description>Abstract
Key points
The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also.
Background
Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up.
Methods
Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as “cases” and rotavirus-negative children as “controls.” Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001–2006) and post-NIP seasons (2009–2013).
Results
The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%–98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons.
Conclusions
Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.</description><subject>Child</subject><subject>Child, Preschool</subject><subject>Editor's Choice</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Finland - epidemiology</subject><subject>Gastroenteritis - epidemiology</subject><subject>Gastroenteritis - prevention & control</subject><subject>Gastroenteritis - virology</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Original</subject><subject>Population Surveillance</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Rotavirus - genetics</subject><subject>Rotavirus Infections - diagnosis</subject><subject>Rotavirus Infections - epidemiology</subject><subject>Rotavirus Infections - prevention & control</subject><subject>Rotavirus Infections - virology</subject><subject>Rotavirus Vaccines - therapeutic use</subject><subject>Seasons</subject><subject>Treatment Outcome</subject><subject>Vaccines, Attenuated - therapeutic use</subject><issn>2048-7193</issn><issn>2048-7207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFvFCEYhidGY5vam2fDTQ-OhYEZmIvJprZdkyYmWg-eCMPA9mtmYcrHrNGf4K8Wu22jF7lAwsPzveStqpeMvmO05yc3M4x4MsN32rEn1WFDhaplQ-XThzPr-UF1jHhDy-pa1irxvDpopOyoovSw-vVlwWwguJGsYXNNzrx3NsPOBYdIoiefYzZX7pbEQNYRZ8hmgp8mQwxIVjknGJZshsmRHO_YHaQF6xVitGBy0V4YzCm6kF2CDEg-LAnChgjyzZmEBAI5hzCZML6onnkzoTu-34-qr-dnV6fr-vLTxcfT1WVthRC5Fg13vuG8F3JoKGucYs1Ifdt3XW97zr2SppN-oJ1lalSypWM78nGgxpZnjPKj6v3eOy_D1o22REtm0nOCrUk_dDSg_70JcK03caclo1IoUQRv7gUp3i4Os94CWjeVT7i4oGaKty0tOVVB3-5RmyJicv5xDKP6T4P6rkG9b7Dgr_6O9gg_9FWA13sgLvP_Vb8Bl6upew</recordid><startdate>20171124</startdate><enddate>20171124</enddate><creator>Hemming-Harlo, Maria</creator><creator>Vesikari, Timo</creator><creator>Uhari, Matti</creator><creator>Renko, Marjo</creator><creator>Salminen, Marjo</creator><creator>Torcel-Pagnon, Laurence</creator><creator>Hartwig, Susanne</creator><creator>Simondon, Francois</creator><creator>Bricout, Hélène</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171124</creationdate><title>Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland</title><author>Hemming-Harlo, Maria ; Vesikari, Timo ; Uhari, Matti ; Renko, Marjo ; Salminen, Marjo ; Torcel-Pagnon, Laurence ; Hartwig, Susanne ; Simondon, Francois ; Bricout, Hélène</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-423ef233947b2012e812d0f59669c933f87a67fb06c18d8750d5d3db0acf23103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Child</topic><topic>Child, Preschool</topic><topic>Editor's Choice</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Finland - epidemiology</topic><topic>Gastroenteritis - epidemiology</topic><topic>Gastroenteritis - prevention & control</topic><topic>Gastroenteritis - virology</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Original</topic><topic>Population Surveillance</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Rotavirus - genetics</topic><topic>Rotavirus Infections - diagnosis</topic><topic>Rotavirus Infections - epidemiology</topic><topic>Rotavirus Infections - prevention & control</topic><topic>Rotavirus Infections - virology</topic><topic>Rotavirus Vaccines - therapeutic use</topic><topic>Seasons</topic><topic>Treatment Outcome</topic><topic>Vaccines, Attenuated - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Hemming-Harlo, Maria</creatorcontrib><creatorcontrib>Vesikari, Timo</creatorcontrib><creatorcontrib>Uhari, Matti</creatorcontrib><creatorcontrib>Renko, Marjo</creatorcontrib><creatorcontrib>Salminen, Marjo</creatorcontrib><creatorcontrib>Torcel-Pagnon, Laurence</creatorcontrib><creatorcontrib>Hartwig, Susanne</creatorcontrib><creatorcontrib>Simondon, Francois</creatorcontrib><creatorcontrib>Bricout, Hélène</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Pediatric Infectious Diseases Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hemming-Harlo, Maria</au><au>Vesikari, Timo</au><au>Uhari, Matti</au><au>Renko, Marjo</au><au>Salminen, Marjo</au><au>Torcel-Pagnon, Laurence</au><au>Hartwig, Susanne</au><au>Simondon, Francois</au><au>Bricout, Hélène</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland</atitle><jtitle>Journal of the Pediatric Infectious Diseases Society</jtitle><addtitle>J Pediatric Infect Dis Soc</addtitle><date>2017-11-24</date><risdate>2017</risdate><volume>6</volume><issue>4</issue><spage>317</spage><epage>323</epage><pages>317-323</pages><issn>2048-7193</issn><eissn>2048-7207</eissn><abstract>Abstract
Key points
The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also.
Background
Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up.
Methods
Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as “cases” and rotavirus-negative children as “controls.” Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001–2006) and post-NIP seasons (2009–2013).
Results
The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%–98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons.
Conclusions
Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>27760800</pmid><doi>10.1093/jpids/piw061</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2048-7193 |
| ispartof | Journal of the Pediatric Infectious Diseases Society, 2017-11, Vol.6 (4), p.317-323 |
| issn | 2048-7193 2048-7207 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7107484 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Child Child, Preschool Editor's Choice Enzyme-Linked Immunosorbent Assay Finland - epidemiology Gastroenteritis - epidemiology Gastroenteritis - prevention & control Gastroenteritis - virology Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Original Population Surveillance Reverse Transcriptase Polymerase Chain Reaction Rotavirus - genetics Rotavirus Infections - diagnosis Rotavirus Infections - epidemiology Rotavirus Infections - prevention & control Rotavirus Infections - virology Rotavirus Vaccines - therapeutic use Seasons Treatment Outcome Vaccines, Attenuated - therapeutic use |
| title | Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T00%3A49%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20High%20Effectiveness%20of%20RotaTeq%20on%20Hospitalizations%20Attributable%20to%20Rotavirus-Associated%20Gastroenteritis%20During%204%20Years%20in%20Finland&rft.jtitle=Journal%20of%20the%20Pediatric%20Infectious%20Diseases%20Society&rft.au=Hemming-Harlo,%20Maria&rft.date=2017-11-24&rft.volume=6&rft.issue=4&rft.spage=317&rft.epage=323&rft.pages=317-323&rft.issn=2048-7193&rft.eissn=2048-7207&rft_id=info:doi/10.1093/jpids/piw061&rft_dat=%3Cproquest_pubme%3E1835504238%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835504238&rft_id=info:pmid/27760800&rft_oup_id=10.1093/jpids/piw061&rfr_iscdi=true |